• Leukemias, lymphomas, and other hematologic cancers

Evomela Generic Name & Formulations

General Description

Melphalan HCl 50mg/vial; lyophilized pwd; for IV infusion after reconstitution.

Pharmacological Class

Alkylating agent.

How Supplied

Single-dose vial (20mL)—1


Generic Availability


Evomela Indications


High-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.

Evomela Dosage and Administration


Give prophylactic antiemetics. Give by IV infusion over 30mins. 100mg/m2 daily for 2 consecutive days (Days -3 and -2) prior to transplantation (Day 0). If patient weighs >130% of their ideal body weight, use adjusted ideal body weight.


Not established.

Evomela Contraindications

Not Applicable

Evomela Boxed Warnings

Boxed Warning

Severe bone marrow suppression. Hypersensitivity. Leukemogenicity.

Evomela Warnings/Precautions


Bone marrow suppression. Monitor CBCs, provide supportive care for infections, anemia, thrombocytopenia until adequate recovery. GI toxicity; provide supportive care. Monitor LFTs. Renal impairment. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or for 3 months (males w. female partners) after the last dose. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).

Evomela Pharmacokinetics

See Literature

Evomela Interactions


Caution with cyclosporine, BCNU.

Evomela Adverse Reactions

Adverse Reactions

Decreased neutrophil, WBC, lymphocyte, and platelet counts, diarrhea, nausea, fatigue, hypokalemia, anemia, vomiting; mucositis, hypersensitivity reactions, hepatic disorders, secondary malignancies, infertility.

Evomela Clinical Trials

See Literature

Evomela Note

Not Applicable

Evomela Patient Counseling

See Literature